Literature DB >> 24032057

Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.

Scott North, Naveen Basappa, Georg Bjarnason, Normand Blais, Christina Canil, Daniel Heng, Jennifer Knox, Neil Reaume, Dean Ruether, Denis Soulières, Pawel Zalewski, Peter Black, Rodney H Breau, Rodney Breau, Michael Jewett, Anil Kapoor, Jean-Baptiste Lattouf, Ronald Moore, Ricardo Rendon, Gerald Todd, Edith Pituskin, Craig Gedye, Lori Wood.   

Abstract

Entities:  

Year:  2013        PMID： 24032057      PMCID： PMC3758938          DOI： 10.5489/cuaj.536

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  40 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

Review 2.  Urologic approaches to metastatic renal cell carcinoma.

Authors:  G H Mickisch
Journal:  Onkologie       Date:  2001-04

3.  Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

Authors:  Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.

Authors:  Viktor Grünwald; Steffen Weikert; Christoph Seidel; Jonas Busch; Antje Johannsen; Martin Fenner; Christoph Reuter; Arnold Ganser; Manfred Johannsen
Journal:  Onkologie       Date:  2011-05-06

6.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

7.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

8.  Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.

Authors: 
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

9.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

10.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544
View more
  4 in total

1.  Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Authors:  Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

2.  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Authors:  J Amdahl; J Diaz; J Park; H R Nakhaipour; T E Delea
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

3.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

Authors:  Scott A North; Naveen Basappa; Joan Basiuk; Georg Bjarnason; Rodney Breau; Christina Canil; Daniel Heng; Michael A S Jewett; Anil Kapoor; Christian Kollmannsberger; Kylea Potvin; M Neil Reaume; J Dean Ruether; Peter Venner; Lori Wood
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

4.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Authors:  M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.